1. Home
  2. ARQT vs GRDN Comparison

ARQT vs GRDN Comparison

Compare ARQT & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • GRDN
  • Stock Information
  • Founded
  • ARQT 2016
  • GRDN 2004
  • Country
  • ARQT United States
  • GRDN United States
  • Employees
  • ARQT N/A
  • GRDN N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • GRDN Retail-Drug Stores and Proprietary Stores
  • Sector
  • ARQT Health Care
  • GRDN Consumer Staples
  • Exchange
  • ARQT Nasdaq
  • GRDN Nasdaq
  • Market Cap
  • ARQT 2.1B
  • GRDN 1.8B
  • IPO Year
  • ARQT 2020
  • GRDN 2024
  • Fundamental
  • Price
  • ARQT $17.71
  • GRDN $26.44
  • Analyst Decision
  • ARQT Strong Buy
  • GRDN Strong Buy
  • Analyst Count
  • ARQT 7
  • GRDN 2
  • Target Price
  • ARQT $19.00
  • GRDN $24.50
  • AVG Volume (30 Days)
  • ARQT 1.6M
  • GRDN 357.8K
  • Earning Date
  • ARQT 11-05-2025
  • GRDN 11-11-2025
  • Dividend Yield
  • ARQT N/A
  • GRDN N/A
  • EPS Growth
  • ARQT N/A
  • GRDN N/A
  • EPS
  • ARQT N/A
  • GRDN N/A
  • Revenue
  • ARQT $263,464,999.00
  • GRDN $1,326,604,000.00
  • Revenue This Year
  • ARQT $72.46
  • GRDN $16.17
  • Revenue Next Year
  • ARQT $31.69
  • GRDN $2.31
  • P/E Ratio
  • ARQT N/A
  • GRDN N/A
  • Revenue Growth
  • ARQT 99.50
  • GRDN 18.53
  • 52 Week Low
  • ARQT $8.03
  • GRDN $14.16
  • 52 Week High
  • ARQT $18.15
  • GRDN $30.39
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 63.97
  • GRDN 49.13
  • Support Level
  • ARQT $16.62
  • GRDN $27.35
  • Resistance Level
  • ARQT $18.15
  • GRDN $30.39
  • Average True Range (ATR)
  • ARQT 0.69
  • GRDN 1.24
  • MACD
  • ARQT 0.03
  • GRDN -0.38
  • Stochastic Oscillator
  • ARQT 85.57
  • GRDN 13.46

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About GRDN Guardian Pharmacy Services Inc. Class A Common Stock

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

Share on Social Networks: